SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company's pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
Часто задаваемые вопросы
В каком секторе работает SciClone Pharmaceuticals (6600)?
SciClone Pharmaceuticals относится к сектору Здравоохранение.
Какова текущая цена акций SciClone Pharmaceuticals (6600)?
По последним данным, цена акций SciClone Pharmaceuticals составляет 43,80 HK$, предыдущее закрытие — 44,28 HK$. За последнюю торговую сессию акции SciClone Pharmaceuticals снизились на -0,48 HK$, что соответствует падению на -1,08%.
Выплачивает ли SciClone Pharmaceuticals (6600) дивиденды?
Нет, SciClone Pharmaceuticals не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у SciClone Pharmaceuticals (6600)?
У компании SciClone Pharmaceuticals бета 0.769, что указывает на более низкую волатильность по сравнению с рынком в целом.
